Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 17 studies | 42% ± 16% | |
peripheral blood | 16 studies | 36% ± 12% | |
brain | 12 studies | 31% ± 10% | |
intestine | 10 studies | 33% ± 15% | |
eye | 10 studies | 46% ± 22% | |
kidney | 9 studies | 38% ± 10% | |
placenta | 5 studies | 26% ± 13% | |
uterus | 5 studies | 41% ± 18% | |
liver | 5 studies | 39% ± 25% | |
lymph node | 5 studies | 40% ± 8% | |
pancreas | 4 studies | 66% ± 20% | |
bone marrow | 4 studies | 23% ± 7% | |
prostate | 4 studies | 35% ± 10% | |
breast | 4 studies | 41% ± 6% | |
adrenal gland | 3 studies | 32% ± 3% | |
thymus | 3 studies | 46% ± 19% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 11018.21 | 2642 / 2642 | 100% | 251.38 | 705 / 705 |
esophagus | 100% | 4430.92 | 1445 / 1445 | 100% | 50.40 | 183 / 183 |
ovary | 100% | 4836.20 | 180 / 180 | 100% | 65.32 | 430 / 430 |
prostate | 100% | 5365.78 | 245 / 245 | 100% | 122.94 | 502 / 502 |
stomach | 100% | 3504.61 | 359 / 359 | 100% | 56.57 | 286 / 286 |
thymus | 100% | 6015.33 | 653 / 653 | 100% | 135.77 | 604 / 605 |
uterus | 100% | 4971.21 | 170 / 170 | 100% | 77.43 | 458 / 459 |
lung | 100% | 5317.88 | 577 / 578 | 100% | 75.41 | 1154 / 1155 |
kidney | 100% | 5615.11 | 89 / 89 | 100% | 90.05 | 898 / 901 |
intestine | 100% | 4776.70 | 966 / 966 | 100% | 63.62 | 525 / 527 |
bladder | 100% | 4381.38 | 21 / 21 | 100% | 76.49 | 502 / 504 |
breast | 100% | 5645.60 | 459 / 459 | 99% | 88.20 | 1111 / 1118 |
adrenal gland | 100% | 6948.03 | 258 / 258 | 99% | 188.31 | 228 / 230 |
skin | 100% | 5456.35 | 1808 / 1809 | 99% | 89.65 | 467 / 472 |
pancreas | 96% | 2051.93 | 315 / 328 | 100% | 91.40 | 178 / 178 |
liver | 93% | 1933.15 | 211 / 226 | 100% | 51.22 | 405 / 406 |
lymph node | 0% | 0 | 0 / 0 | 100% | 107.76 | 29 / 29 |
muscle | 100% | 6228.19 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 5310.36 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 61.65 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 52.25 | 1 / 1 |
adipose | 100% | 5461.48 | 1203 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 100% | 6999.68 | 928 / 929 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 6833.23 | 1333 / 1335 | 0% | 0 | 0 / 0 |
heart | 99% | 6888.46 | 854 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 96% | 65.75 | 77 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0032781 | Biological process | positive regulation of ATP-dependent activity |
GO_0000045 | Biological process | autophagosome assembly |
GO_1901799 | Biological process | negative regulation of proteasomal protein catabolic process |
GO_0070972 | Biological process | protein localization to endoplasmic reticulum |
GO_0006891 | Biological process | intra-Golgi vesicle-mediated transport |
GO_0000422 | Biological process | autophagy of mitochondrion |
GO_0015031 | Biological process | protein transport |
GO_0006914 | Biological process | autophagy |
GO_0097352 | Biological process | autophagosome maturation |
GO_0006995 | Biological process | cellular response to nitrogen starvation |
GO_0031410 | Cellular component | cytoplasmic vesicle |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0000421 | Cellular component | autophagosome membrane |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0000139 | Cellular component | Golgi membrane |
GO_0005829 | Cellular component | cytosol |
GO_0005776 | Cellular component | autophagosome |
GO_0005737 | Cellular component | cytoplasm |
GO_0048487 | Molecular function | beta-tubulin binding |
GO_0050811 | Molecular function | GABA receptor binding |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0000149 | Molecular function | SNARE binding |
GO_0008017 | Molecular function | microtubule binding |
GO_0051117 | Molecular function | ATPase binding |
GO_0008429 | Molecular function | phosphatidylethanolamine binding |
GO_0005515 | Molecular function | protein binding |
Gene name | GABARAPL2 |
Protein name | Gamma-aminobutyric acid receptor-associated protein-like 2 (GABA(A) receptor-associated protein-like 2) (Ganglioside expression factor 2) (GEF-2) (General protein transport factor p16) (Golgi-associated ATPase enhancer of 16 kDa) (GATE-16) (MAP1 light chain 3-related protein) GABA type A receptor associated protein like 2 (GABA(A) receptor-associated protein-like 2, isoform CRA_a) GABA type A receptor associated protein like 2 |
Synonyms | GEF2 hCG_21766 FLC3A |
Description | FUNCTION: Ubiquitin-like modifier involved in intra-Golgi traffic (By similarity). Modulates intra-Golgi transport through coupling between NSF activity and SNAREs activation (By similarity). It first stimulates the ATPase activity of NSF which in turn stimulates the association with GOSR1 (By similarity). Involved in autophagy . Plays a role in mitophagy which contributes to regulate mitochondrial quantity and quality by eliminating the mitochondria to a basal level to fulfill cellular energy requirements and preventing excess ROS production . Whereas LC3s are involved in elongation of the phagophore membrane, the GABARAP/GATE-16 subfamily is essential for a later stage in autophagosome maturation . . |
Accessions | ENST00000565057.5 P60520 H3BU36 H3BQ50 ENST00000037243.7 ENST00000568455.1 H3BSM5 ENST00000563744.1 |